Table 1.
Baseline characteristics in the 813 patients enrolled in CARE-HF
| CRT group |
Medical therapy group |
IHD vs. non-IHD (P-value) | |||
|---|---|---|---|---|---|
| IHD n = 186 | Non-IHD n = 223 | IHD n = 153 | Non-IHD n = 250 | ||
| Male sex, n (%) | 154 (82.80) | 150 (67.26) | 132 (86.27) | 161 (64.40) | <0.0001 |
| Age (years), mean (SD) | 67.69 (9.02) | 63.73 (10.72) | 67.94 (8.82) | 63.44 (10.41) | <0.0001 |
| NYHA class IV, n (%) | 14 (7.53) | 9 (4.04) | 14 (9.15) | 13 (5.20) | 0.039 |
| Systolic blood pressure (mmHg), mean (SD) | 116.69 (16.44) | 118.21 (17.41) | 115.45 (18.17) | 118.70 (17.89) | 0.12 |
| LVEF (%), mean (SD) | 25.30 (5.72) | 25.47 (6.19) | 26.20 (6.01) | 25.27 (6.15) | 0.19 |
| LVESV (cm3), mean (SD) | 120.86 (42.66) | 129.98 (52.83) | 123.70 (40.09) | 130.81 (54.79) | 0.22 |
| Mitral regurgitation, median (IQR)a | 23.57 (14.37) | 23.59 (16.15) | 23.11 (13.18) | 24.51 (15.33) | 0.95 |
| ACE-I/ARB, n (%) | 175 (94.09) | 212 (95.07) | 140 (91.50) | 243 (97.20) | 0.052 |
| Digoxin, n (%) | 75 (40.32) | 90 (40.36) | 54 (35.29) | 127 (50.80) | 0.031 |
| β-Blocker, n (%) | 124 (66.67) | 174 (78) | 102 (66.67) | 186 (74.40) | 0.003 |
| Loop diuretics ≥80 mg per day furosemide or equivalent, n (%) | 101 (54.30) | 74 (33.18) | 89 (58.17) | 88 (35.20) | <0.0001 |
| GFR (mL/min), median (IQR) | 56.93 (43.74–70.63) | 61.43 (49.41–75.61) | 52.51 (42.75–65.84) | 64.16 (49.99–77.54) | <0.0001 |
| NT-proBNP (pg/mL), median (IQR) | 2182 (888–4888) | 1725 (651–3992) | 2064 (1057–4787) | 1658 (592–3611) | 0.0021 |
| QRS (ms), mean (SD) | 163.47 (18.95) | 167.41 (20.85) | 161.84 (20.33) | 166.25 (17.57) | 0.0012 |
| IVMD >40, n (%) | 64 (38.10) | 117 (59.39) | 43 (31.85) | 144 (61.28) | <0.0001 |
| IVMD (ms), mean (SD) | 41.44 (26.30) | 56.70 (29.61) | 37.86 (24.55) | 54.64 (26.75) | <0.0001 |
| Aorta pre-ejection time ≥140 ms, n (%) | 101 (58.72) | 166 (82.59) | 77 (55.40) | 193 (80.75) | <0.0001 |
| Pulmonary pre-ejection time ≥140 ms, n (%) | 25 (14.88) | 45 (22.61) | 23 (17.04) | 51 (21.43) | 0.0471 |
ACE-I, angiotensin-converting enzyme-inhibitor; ARB, angiotensin receptor blocker; GFR, glomerular filtration rate; IVMD, interventricular mechanical delay; NT-proBNP, brain natriuretic peptide.
aThe area of the mitral regurgitation jet was calculated as the area of the colour flow Doppler regurgitant jet divided by the area of the left atrium in systole, both in square centimetres.